Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [2092]

ESMO 2019: Immune therapy eliminates tumour cells in early triple negative breast cancer

ESMO 2019: Immune therapy eliminates tumour cells in early triple negative breast cancer

ESMO 2019: More ovarian cancer patients benefit from maintenance combined targeted therapy

ESMO 2019: More ovarian cancer patients benefit from maintenance combined targeted therapy

ESMO 2019: Front-line osimertinib improves overall survival in EGFR-mutation positive NSCLC

ESMO 2019: Front-line osimertinib improves overall survival in EGFR-mutation positive NSCLC

ESMO 2019: Two immunotherapy drug combination offers chemotherapy-free option for advanced NSCLC

ESMO 2019: Two immunotherapy drug combination offers chemotherapy-free option for advanced NSCLC

ESMO 2019: Men with prostate cancer can be spared radiotherapy after surgery

ESMO 2019: Men with prostate cancer can be spared radiotherapy after surgery

Trial finds high-dose radiation effective for men whose prostate cancer has spread

Trial finds high-dose radiation effective for men whose prostate cancer has spread

Women equally satisfied with cosmetic results of partial, whole breast radiation after lumpectomy

Women equally satisfied with cosmetic results of partial, whole breast radiation after lumpectomy

Investigational drug with immunotherapy may provide new therapeutic opportunity for patients previously treated for kidney and lung cancer

Investigational drug with immunotherapy may provide new therapeutic opportunity for patients previously treated...

Do the costs of cancer drugs receive enough attention?

Do the costs of cancer drugs receive enough attention?

Durvalumab combined with chemotherapy improves overall survival in patients with lung cancer

Durvalumab combined with chemotherapy improves overall survival in patients with lung cancer

More from ecancer